<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059862</url>
  </required_header>
  <id_info>
    <org_study_id>Aryl-IMMUNE</org_study_id>
    <nct_id>NCT03059862</nct_id>
  </id_info>
  <brief_title>The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation</brief_title>
  <acronym>Aryl-IMMUNE</acronym>
  <official_title>The Role of Tryptophan on Aryl Hydrocarbon Receptor Activation: a Randomized, Double Blind, Placebo-controlled, Crossover Design Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Agency, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the role of dietary L-tryptophan, an essential amino acid, in the
      activation of a specific cellular component: the aryl hydrocarbon receptor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor implicated in
      a range of key cellular events. In the gut, AHR is crucial for maintaining intestinal barrier
      immune homeostasis. The physiology of the AHR, however, is not completely understood; its
      precise gut luminal activators and functional consequences are unknown.

      Some AHR ligands originate from the diet. Commensals play crucial roles in metabolizing
      tryptophan and other amino acids such as tyrosine, with the subsequent production of
      tryptophan metabolites. Previous studies show that inflammatory bowel disease (IBD) patients
      have impaired production of AHR agonists by the microbiota. Furthermore, dietary
      supplementation with tryptophan ameliorates clinical parameters of colitis in rodent models.
      Whether these findings translate into human pathophysiology has not been explored.

      In the present study, the investigators will evaluate the effect of high- versus
      low-tryptophan diet on AHR activation in healthy participants. Briefly, participants will be
      instructed to follow a standardized low-tryptophan diet and will be randomized to a 3-week
      L-tryptophan supplement or placebo. Later, after a 2-week washout period, participants will
      crossover to the other arm. In addition, the effect of tryptophan and microbiota-derived
      metabolites on AHR activation will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects will be following a standardized low-tryptophan diet and randomized to L-tryptophan supplements or placebo, for three weeks. After a 2 weeks washout period, subjects will crossover to the other arm.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AHR activation levels in stool and duodenal content.</measure>
    <time_frame>three weeks</time_frame>
    <description>Changes in AHR activation levels will be assessed in stool and duodenal samples before and after the intervention (high- and low-tryptophan diets) using an AHR cell-reporter line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial and fungal microbiota composition in stool, duodenum and rectum/sigmoid biopsies.</measure>
    <time_frame>Three weeks</time_frame>
    <description>Changes in bacterial and fungal microbiota composition will be assessed before and after the intervention in stool samples, duodenum and rectum biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tryptophan metabolites levels, including host and bacterial catabolites, in blood, urine and stool.</measure>
    <time_frame>Three weeks</time_frame>
    <description>Changes in tryptophan metabolites leves will be compared before and after the intervention, in blood, urine and stool samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA levels in duodenal and rectum/sigmoid biopsies.</measure>
    <time_frame>three weeks</time_frame>
    <description>Changes in mRNA levels in duodenal and rectum/sigmoid biopsies will be assessed before and after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in serum.</measure>
    <time_frame>three weeks.</time_frame>
    <description>Changes in cytokines in the serum (IL-22, IL-6, IL-2, IL-10, IL-12p70, IL-23p19, IFNγ, TNFα and CRP will be measured by ELISA in cell culture supernatants after stimulation with LPS, curdlan and ConA ) will be measured before and after the intervention and patients will be grouped into two categories for each measurement: high vs. low, according to the cutoff reference test value for each of the cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>three weeks.</time_frame>
    <description>Changes in gastrointestinal symptoms before and after the intervention will be assessed using a validated questionnaire (The Gastrointestinal Symptoms Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>three weeks</time_frame>
    <description>Changes in mood before and after the intervention will be assessed using a validated questionnaire (Hospital anxiety and depression scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diet Modification</condition>
  <arm_group>
    <arm_group_label>Low-tryptophan diet and L-tryptophan.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-tryptophan diet and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-tryptophan</intervention_name>
    <description>3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.</description>
    <arm_group_label>Low-tryptophan diet and L-tryptophan.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.</description>
    <arm_group_label>Low-tryptophan diet and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer between 18 and 75 years of age.

        Exclusion Criteria:

          -  Rome IV criteria for any functional gastrointestinal disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Premysl Bercik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Department of Medicine, Division of Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia Causada Calo, MD</last_name>
    <phone>+19059020215</phone>
    <email>causadan@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Verdu, MD, PhD</last_name>
    <phone>905.523.6048</phone>
    <email>verdue@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Causada Calo, MD</last_name>
      <phone>9059020215</phone>
      <email>causadan@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>María Inés Pinto-Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Verdu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Hansen, Dietician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Causada Calo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Premysl Bercik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://farncombe.mcmaster.ca/</url>
    <description>This is our Research Institute Website</description>
  </link>
  <reference>
    <citation>Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007 Jul 31;581(19):3608-15. Epub 2007 Mar 30. Review.</citation>
    <PMID>17412325</PMID>
  </reference>
  <reference>
    <citation>Behnsen J, Raffatellu M. Keeping the peace: aryl hydrocarbon receptor signaling modulates the mucosal microbiota. Immunity. 2013 Aug 22;39(2):206-7. doi: 10.1016/j.immuni.2013.08.012.</citation>
    <PMID>23973218</PMID>
  </reference>
  <reference>
    <citation>Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6(2):101-97. Review.</citation>
    <PMID>6371429</PMID>
  </reference>
  <reference>
    <citation>Cynober L, Bier DM, Kadowaki M, Morris SM Jr, Elango R, Smriga M. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly. J Nutr. 2016 Dec;146(12):2652S-2654S. Epub 2016 Nov 9. Review.</citation>
    <PMID>27934658</PMID>
  </reference>
  <reference>
    <citation>Hubbard TD, Murray IA, Bisson WH, Lahoti TS, Gowda K, Amin SG, Patterson AD, Perdew GH. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci Rep. 2015 Aug 3;5:12689. doi: 10.1038/srep12689.</citation>
    <PMID>26235394</PMID>
  </reference>
  <reference>
    <citation>Kiss EA, Vonarbourg C, Kopfmann S, Hobeika E, Finke D, Esser C, Diefenbach A. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science. 2011 Dec 16;334(6062):1561-5. doi: 10.1126/science.1214914. Epub 2011 Oct 27.</citation>
    <PMID>22033518</PMID>
  </reference>
  <reference>
    <citation>Kiss EA, Vonarbourg C. Aryl hydrocarbon receptor: a molecular link between postnatal lymphoid follicle formation and diet. Gut Microbes. 2012 Nov-Dec;3(6):577-82. doi: 10.4161/gmic.21865. Epub 2012 Aug 22. Review.</citation>
    <PMID>22909905</PMID>
  </reference>
  <reference>
    <citation>Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, Wilhelm C, Veldhoen M. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011 Oct 28;147(3):629-40. doi: 10.1016/j.cell.2011.09.025. Epub 2011 Oct 13.</citation>
    <PMID>21999944</PMID>
  </reference>
  <reference>
    <citation>Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D'Angelo C, Massi-Benedetti C, Fallarino F, Carvalho A, Puccetti P, Romani L. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013 Aug 22;39(2):372-85. doi: 10.1016/j.immuni.2013.08.003.</citation>
    <PMID>23973224</PMID>
  </reference>
  <reference>
    <citation>Qiu J, Heller JJ, Guo X, Chen ZM, Fish K, Fu YX, Zhou L. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012 Jan 27;36(1):92-104. doi: 10.1016/j.immuni.2011.11.011. Epub 2011 Dec 15.</citation>
    <PMID>22177117</PMID>
  </reference>
  <results_reference>
    <citation>Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9.</citation>
    <PMID>27158904</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunity</keyword>
  <keyword>Aryl-hydrocarbon receptor</keyword>
  <keyword>immune homeostasis</keyword>
  <keyword>microbiota</keyword>
  <keyword>tryptophan</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

